NasdaqGM:RDNTHealthcare
RadNet (RDNT) Valuation Check After Short-Seller Critique and Raymond James’ Defense of Its AI Story
RadNet (RDNT) has been on a rollercoaster after Hunterbrook Capital’s short report hammered the stock, only for Raymond James to step in and defend the company, remaining positive on its long term outlook.
See our latest analysis for RadNet.
Against that backdrop, RadNet’s share price has whipsawed but is still up solidly on a year to date basis. Its exceptional three year total shareholder return suggests the long term momentum story is intact despite near term volatility.
If this kind of...